Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG007 in Unresectable Locally Advanced or Metastatic Solid Tumors
NCT07066657Phase 1Recruiting
- Sponsor
- ArriVent BioPharma
- Start
- Jul 2025
- Primary completion
- Mar 2028
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of MRG007 in solid tumor, colorectal cancer (CRC), gastric cancer (GC) and 1 more (2 arms), sponsored by ArriVent BioPharma. Primary endpoints: Dose Limiting Toxicity at Day 21, Serious Adverse Events and 3 more. Started Jul 2025; status: recruiting.
02
Drugs
MRG007
03
Conditions
solid tumorcolorectal cancer (CRC)gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07066657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07066657.